Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

American Cancer Society announces new research, training grants for fiscal year 2013

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 175 national research and training grants totaling $79,073,250 for fiscal year 2013.

9 Apr 2013

FDA grants Breakthrough Therapy Designation for ibrutinib as monotherapy for CLL patients

Pharmacyclics, Inc. announced today that the U.S. Food and Drug Administration has granted an additional Breakthrough Therapy Designation for the investigational oral agent ibrutinib as monotherapy for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma patients with deletion of the short arm of chromosome 17 (deletion 17p).

8 Apr 2013

CRG researchers reprogramme lymphoma and leukaemia cells to halt malignancy

Researchers from the Centre for Genomic Regulation (CRG) in Barcelona reprogramme lymphoma and leukaemia cells to halt their malignancy. Resulting cells remain benign even when no longer subjected to treatment and reduce likelihood of developing new tumours.

3 Apr 2013

Researchers discover new type of deadly intestinal lymphoma common in Asia

An international research team has identified a new type of deadly intestinal lymphoma that is particularly common in Asia. The team, led by clinician-scientists from the SingHealth Academic Healthcare Cluster, also developed a new diagnostic test to accurately identify these patients.

2 Apr 2013

Novel cell therapy effective in treating aggressive form of childhood leukemia

Two children with an aggressive form of childhood leukemia had a complete remission of their disease—showing no evidence of cancer cells in their bodies—after treatment with a novel cell therapy that reprogrammed their immune cells to rapidly multiply and destroy leukemia cells.

26 Mar 2013

Scientists develop new chemo drug that fights cancer without impacting fertility

A new gentler chemotherapy drug in the form of nanoparticles has been designed by Northwestern Medicine- scientists to be less toxic to a young woman's fertility but extra tough on cancer. This is the first cancer drug tested while in development for its effect on fertility using a novel in vitro test.

25 Mar 2013

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

Pfizer Inc. announced today that the Japanese Ministry of Health, Labor and Welfare has approved XELJANZ (tofacitinib citrate) for the treatment of adults with rheumatoid arthritis who have had an inadequate response to existing therapies.

25 Mar 2013

Researchers expand hematopoietic stem cells for bone marrow transplantation

More than 50,000 stem cell transplants are performed each year worldwide. A research team led by Weill Cornell Medical College investigators may have solved a major issue of expanding adult hematopoietic stem cells (HSCs) outside the human body for clinical use in bone marrow transplantation -- a critical step towards producing a large supply of blood stem cells needed to restore a healthy blood system.

25 Mar 2013

Researchers identify a new approach for treating brain metastases associated with lung cancer

Lung cancer is the world's most common cause of death from cancer. In Austria, around 4,000 people develop this type of cancer every year. One particular problem is the development of brain metastases in association with the lung tumour.

24 Mar 2013

Investigators examine effectiveness of probiotics for cancer treatment

One may not think of probiotics -- like those found in yogurt that promote good digestive health -- as a weapon used in the fight against cancer. But that is the focus of investigators at The Cancer Institute of New Jersey, who are examining the effectiveness of probiotics as they relate to the outcomes of bone marrow transplant for patients with blood cancers.

21 Mar 2013

Survivors of childhood leukemia and lymphoma are at greater risk of chronic fatigue: Study

Chronic fatigue, a persistent lack of energy that does not improve with rest, is at least three times more prevalent among adult survivors of acute lymphoblastic leukemia and lymphoma experienced during childhood or adolescence than in the general adult population, according to an article in Journal of Adolescent and Young Adult Oncology, a multidisciplinary peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

21 Mar 2013

St. Jude Children's Research Hospital receives patent for genetically modified human immune cells for caner therapy

The United States Patent and Trademark Office today awarded St. Jude Children's Research Hospital U.S. patent number 8,399,645 for St. Jude's invention of compositions for genetically modifying human immune cells so they can destroy some of the most common forms of cancer in children and adults.

20 Mar 2013

Results from GTx's Phase 2 clinical trial of enobosarm published online

GTx, Inc. today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition the results from GTx's randomized, double-blind, placebo-controlled Phase 2 clinical trial of enobosarm to assess its effects on muscle wasting and physical function in patients with cancer.

15 Mar 2013

Scientists to create new human monoclonal antibody targeting protein associated with cancer

Researchers have discovered a unique monoclonal antibody that can effectively reach inside a cancer cell, a key goal for these important anticancer agents, since most proteins that cause cancer or are associated with cancer are buried inside cancer cells.

14 Mar 2013

Study finds how to shut down Bcl6 in diffuse large B-cell lymphoma

The powerful master regulatory transcription factor called Bcl6 is key to the survival of a majority of aggressive lymphomas, which arise from the B-cells of the immune system. The protein has long been considered too complex to target with a drug since it is also crucial to the healthy functioning of many immune cells in the body, not just B cells gone bad.

4 Mar 2013

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).

4 Mar 2013

Study instructs how to design new, more powerful vaccine formulas for cancer

Cancer vaccines that attempt to stimulate an immune system assault fail because the killer T cells aimed at tumors instead find the vaccination site a more inviting target, scientists at The University of Texas MD Anderson Cancer Center report in Nature Medicine.

4 Mar 2013

The clock runs out on averting sequestration

Time ticked down to March 1 -- also known as sequestration D-day -- without the White House and lawmakers finding a way to avert the scheduled cuts.

3 Mar 2013

Global inhibition of all Notch signals would not be safe after bone marrow transplantation

Bone marrow transplant is a key treatment for patients with leukemia, lymphoma, multiple myeloma and other blood disorders. University of Michigan researchers have discovered that inhibiting a signaling pathway in some of the transplanted cells could prevent the most serious potential complications of the procedure, a conflict between the transplanted cells and the recipient's own tissue called graft-versus-host disease.

2 Mar 2013

First Edition: March 1, 2013

Kaiser Health News staff writer Mary Agnes Carey reports: "David P. Blom is one of thousands of hospital executives across the country who are bracing for a reduction in Medicare payments as part of a series of federal spending cuts that begin Friday. Blom, 58, is president and chief executive officer of OhioHealth, a Columbus, Ohio, based not-for-profit health care system that includes 18 hospitals, 23 health and surgery centers, home-health providers and other facilities."

1 Mar 2013

Lymphoma News and Research

Further Reading

American Cancer Society announces new research, training grants for fiscal year 2013

FDA grants Breakthrough Therapy Designation for ibrutinib as monotherapy for CLL patients

CRG researchers reprogramme lymphoma and leukaemia cells to halt malignancy

Researchers discover new type of deadly intestinal lymphoma common in Asia

Novel cell therapy effective in treating aggressive form of childhood leukemia

Scientists develop new chemo drug that fights cancer without impacting fertility

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

Researchers expand hematopoietic stem cells for bone marrow transplantation

Researchers identify a new approach for treating brain metastases associated with lung cancer

Investigators examine effectiveness of probiotics for cancer treatment

Survivors of childhood leukemia and lymphoma are at greater risk of chronic fatigue: Study

St. Jude Children's Research Hospital receives patent for genetically modified human immune cells for caner therapy

Results from GTx's Phase 2 clinical trial of enobosarm published online

Scientists to create new human monoclonal antibody targeting protein associated with cancer

Study finds how to shut down Bcl6 in diffuse large B-cell lymphoma

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

Study instructs how to design new, more powerful vaccine formulas for cancer

The clock runs out on averting sequestration

Global inhibition of all Notch signals would not be safe after bone marrow transplantation

First Edition: March 1, 2013

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News